CL
OCUL icon

CSS LLC’s Ocular Therapeutix OCUL Stock Holding History

CSS LLC’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-120,700
Closed -$339K – 846
2022
Q4 		$339K Sell
120,700
-19,400
-14% -$64.2K 0.02% 487
2022
Q3 		$581K Buy
140,100
+120,100
+601% +$605K 0.03% 482
2022
Q2 		$80K Buy
+20,000
New +$75.6K ﹤0.01% 909
2022
Q1 		– Sell
-20,000
Closed -$139K – 1270
2021
Q4 		$139K Buy
20,000
+10,200
+104% +$79.2K ﹤0.01% 966
2021
Q3 		$98K Buy
+9,800
New +$110K ﹤0.01% 980
2021
Q2 		– Sell
-13,200
Closed -$217K – 1145
2021
Q1 		$217K Buy
13,200
+1,200
+10% +$23.1K 0.01% 751
2020
Q4 		$248K Sell
12,000
-16,300
-58% -$242K 0.01% 598
2020
Q3 		$215K Sell
28,300
-39,200
-58% -$325K 0.01% 564
2020
Q2 		$563K Sell
67,500
-21,500
-24% -$143K 0.03% 365
2020
Q1 		$441K Buy
+89,000
New +$439K 0.03% 319

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CSS LLC's OCUL Position: Q1 2023 in Review

CSS LLC sold out of Ocular Therapeutix (OCUL) in Q1 2023, closing a stake of 25,809 shares — an estimated $72.5K sold.

CSS LLC first reported a position in OCUL in Q1 2020 and held it in 11 quarters. The position peaked at $580K in Q4 2020. 127 funds tracked by Wall St. Rank hold OCUL as of Q1 2023.

  • CSS LLC reported no remaining Ocular Therapeutix position as of Q1 2023 after selling out during the quarter.
  • CSS LLC sold 25,809 Ocular Therapeutix shares in Q1 2023, an estimated $72.5K.
  • CSS LLC first reported a position in Ocular Therapeutix in Q1 2020 and held it in 11 quarters.
  • CSS LLC's Ocular Therapeutix position peaked at $580K in Q4 2020.
  • 127 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2023.

Based on CSS LLC's 13F filing for Q1 2023, filed 15 May 2023.